Proactive Investors - Run By Investors For Investors

Coherus BioSciences earns Baird upgrade after sales of its flagship drug comfortably exceed expectations

Sales of its drug Udenyca are expected to be between $36 million and $38 million for the fiscal first quarter
White blood cells gathering
Udenyca is a biosimilar that stimulates white blood cell growth in patients who have received cancer medications

Coherus BioSciences, Inc. (NASDAQ:CHRS) shares surged after announcing late Friday that preliminary sales of its drug Udenyca are expected to be between $36 million and $38 million for the fiscal first quarter.

Investors injected new life into the stock, boosting the share price 6.9% to $15.49.

Its sales performance caught the attention of Baird analyst Michael Ulz, who reiterated the firm’s Outperform rating and its price target of $28 for Coherus on Monday.

Udenyca is a biosimilar that stimulates white blood cell growth in patients who have received cancer medications. The consensus estimate for its quarterly sales was a $3.9 million, which the drugmaker wildly exceeded.

Baird’s own estimate was even lower at $2.8 million.

The Redwood City, California company first launched Udenyca in January. Additional updates are expected to be released on May 9.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

View full CHRS profile View Profile

Coherus BioSciences Timeline

Related Articles

A stomach adenocarcinoma
February 12 2019
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.
word cancer under magnifying glass
May 01 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.
1550850611_CancerHeadline.jpg
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use